Sei Investments Co. Has $2.21 Million Position in Bausch + Lomb Corporation $BLCO

Sei Investments Co. boosted its stake in shares of Bausch + Lomb Corporation (NYSE:BLCO) by 100.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 139,266 shares of the company’s stock after purchasing an additional 69,633 shares during the period. Sei Investments Co.’s holdings in Bausch + Lomb were worth $2,214,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. increased its stake in Bausch + Lomb by 729.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after buying an additional 2,042 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of Bausch + Lomb by 104.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after buying an additional 1,136 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after buying an additional 1,403 shares during the period. Focus Partners Wealth purchased a new position in shares of Bausch + Lomb during the 3rd quarter valued at $170,000. Finally, Invesco Ltd. acquired a new position in shares of Bausch + Lomb in the fourth quarter worth $178,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

Bausch + Lomb Trading Up 2.4%

Shares of NYSE:BLCO opened at $16.73 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $5.98 billion, a PE ratio of -34.86, a P/E/G ratio of 0.54 and a beta of 0.56. Bausch + Lomb Corporation has a 1 year low of $13.53 and a 1 year high of $18.92. The firm has a fifty day moving average price of $16.02 and a 200 day moving average price of $16.40.

Analyst Ratings Changes

BLCO has been the subject of several recent research reports. Citigroup increased their price objective on Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Deutsche Bank Aktiengesellschaft set a $16.00 target price on Bausch + Lomb in a research report on Thursday, April 30th. UBS Group initiated coverage on Bausch + Lomb in a research note on Thursday, July 30th. They set a “buy” rating and a $21.00 price target for the company. Wall Street Zen upgraded Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Finally, HC Wainwright boosted their price target on Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $18.75.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.